Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)

NCT06834282 is registered in ClinicalTrials.gov with CERo Therapeutics Holdings, Inc. as lead sponsor.

NCT NCT06834282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06834282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)
Lead sponsor
CERo Therapeutics Holdings, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
April 7, 2025
Completion date
December 31, 2029
Enrollment
18 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, aml, refractory acute myeloid leukemia